Wall Street analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $3.03 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Advaxis’ earnings. The lowest sales estimate is $3.00 million and the highest is $3.05 million. Advaxis reported sales of $3.79 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 20.1%. The firm is scheduled to issue its next quarterly earnings results on Friday, March 9th.
According to Zacks, analysts expect that Advaxis will report full year sales of $3.03 million for the current financial year, with estimates ranging from $12.21 million to $13.00 million. For the next year, analysts anticipate that the business will post sales of $12.68 million per share, with estimates ranging from $12.27 million to $13.10 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Advaxis.
Advaxis (NASDAQ:ADXS) last issued its earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.02). Advaxis had a negative return on equity of 114.00% and a negative net margin of 776.63%. The business had revenue of $1.76 million for the quarter, compared to the consensus estimate of $3.05 million.
Shares of Advaxis (ADXS) traded down $0.13 during midday trading on Friday, hitting $2.51. The stock had a trading volume of 763,024 shares, compared to its average volume of 890,758. Advaxis has a one year low of $2.43 and a one year high of $10.06. The company has a market cap of $103.08, a P/E ratio of -1.09 and a beta of 0.70.
A number of large investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. lifted its holdings in Advaxis by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,321 shares of the biotechnology company’s stock worth $840,000 after purchasing an additional 817 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Advaxis by 2.6% during the 2nd quarter. Wells Fargo & Company MN now owns 44,813 shares of the biotechnology company’s stock worth $290,000 after purchasing an additional 1,144 shares during the last quarter. TIAA CREF Investment Management LLC lifted its holdings in Advaxis by 2.4% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 98,164 shares of the biotechnology company’s stock worth $637,000 after purchasing an additional 2,329 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Advaxis by 10.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 2,969 shares during the last quarter. Finally, Voya Investment Management LLC lifted its holdings in Advaxis by 20.3% during the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 2,975 shares during the last quarter. 42.63% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2018/02/18/3-03-million-in-sales-expected-for-advaxis-inc-adxs-this-quarter.html.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.